Kindred Biosciences may develop drugs for pets, but the company's December IPO has been anything but a dog. The stock has more than doubled since it started trading, but the company's employees are hard at work developing its osteoarthritis drug which CEO Dr. Richard Chin expects to be on the market by 2015. Chin says the company raised sufficient cash to be cash flow positive in the next 3 years and he expects up to 3 product launches in that time. As for a potential tie-up with fellow animal health provider Zoetis, Chin says Kindred is concentrating on being a stand alone company for now.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

2 Animal Drugmakers Worth a Sniff

The Final Fine-Tuned Gad Value Investment Portfolio for 2017

The 2017 Gad Value Investment Fund, Part 2

2 Bargains That Are Hiding in Plain Sight